



## Effect of RNA concentration on cDNA synthesis for DNA amplification.

W V Williams, H Rosenbaum and D B Weiner

*Genome Res.* 1992 2: 86-88

Access the most recent version at doi:[10.1101/gr.2.1.86](https://doi.org/10.1101/gr.2.1.86)

---

**References** This article cites 8 articles, 5 of which can be accessed free at:  
<http://genome.cshlp.org/content/2/1/86.full.html#ref-list-1>

### License

**Email Alerting Service** Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

---

An advertisement banner with a teal background. On the left, the text reads "CRISPR and RNAi Genetic Screening. Your new superpower." In the center, there is a white box with the text "LEARN MORE". On the right, there is a photograph of a woman wearing a red and white superhero cape and mask, and the Cellecta logo, which consists of a green molecular structure and the word "CELLECTA" in white capital letters.

CRISPR and RNAi Genetic Screening.  
Your new superpower.

LEARN MORE

CELLECTA

---

To subscribe to *Genome Research* go to:  
<https://genome.cshlp.org/subscriptions>

---

Copyright © Cold Spring Harbor Laboratory Press

# Effect of RNA Concentration on cDNA Synthesis for DNA Amplification

William V. Williams,<sup>1,2</sup>  
Helga Rosenbaum,<sup>1</sup> and  
David B. Weiner<sup>1,3</sup>

<sup>1</sup>The Rheumatology Section, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104; <sup>2</sup>The Pediatric Rheumatology Section, The Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania 19104; <sup>3</sup>The Biotechnology Center, The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania 19104

DNA amplification utilizing the polymerase chain reaction (PCR) has greatly enhanced the ability to detect the presence of rare mRNA species in cells. By employing specific sense and antisense oligonucleotide primers with thermostable DNA polymerase, PCR allows amplification of target sequences by several log orders of magnitude.<sup>(1,2)</sup> This technique is being used increasingly to quantify rare mRNA species from cells.<sup>(3-6)</sup> In these studies, it is critical that the initial cDNA synthesis step be well controlled and optimized to produce a uniform substrate for amplification. We have examined RNA concentration in the initial cDNA synthesis reaction to optimize it for PCR amplification of both high- and low-abundance messages.

## MATERIALS AND METHODS

### Cells

Jurkat cells (kindly provided by G. Gaulton, Department of Pathology, University of Pennsylvania School of Medicine) were grown in RPMI-1640 with added penicillin/streptomycin, L-glutamine, and 10% fetal calf serum, and passaged twice weekly prior to use.

### RNA Isolation and cDNA Synthesis

Cells were centrifuged (1200 rpm/10 min) and lysed in GITC-containing lysis buffer (4 M guanidine isothiocyanate, 0.5% *N*-lauroyl sarcosyl, 25 mM sodium citrate, 0.1 M  $\beta$ -mercaptoethanol). The lysate was extracted once with phenol, once with phenol/chloroform/isoamyl alcohol, and RNA-precipitated in 50% EtOH. The RNA pellet was resuspended in 50  $\mu$ l diethylpyrocarbonate (DEP)-treated water, analyzed by agarose gel electrophoresis, and quantified spectrophotometrically (OD<sub>260</sub>). Varying concentrations of RNA were utilized to synthesize cDNA with random priming in the following reaction mixture of 20  $\mu$ l: 200 or 400 units of Moloney murine leukemia virus reverse transcriptase with a 1:5 dilution of 5 $\times$  reverse transcriptase buffer (includes dithiothreitol), and 4 units of RNase inhibitor (all from GIBCO/BRL, Gaithersburg, MD), 0.6 or 1.2  $\mu$ g of random oligonucleotides (mostly hexamers) (from Pharmacia LKB Biotechnology, Piscataway, NJ), and 0.5 or 1 mM dNTPs (equimolar in each dNTP, from Boehringer Mannheim

GmbH, Germany). Following a 10-min preincubation at 25°C, the reaction was carried out for 1 hr at 42°C, then 95°C for 5 min, followed by storage at -20°C until use.

### DNA Amplification

cDNA was amplified utilizing *Thermus aquaticus* DNA polymerase (*Taq* polymerase) and standard reaction conditions suggested by the manufacturer (Perkin-Elmer Cetus Corp., Norwalk, CT). If cDNA was used directly, it was diluted at least 1:20 in the PCR reaction, thereby minimizing the concentration of reagents from the cDNA synthesis step. The reaction mixture (25  $\mu$ l) contained a 1:10 dilution of 10 $\times$  reaction buffer, dNTPs (final concentration 200  $\mu$ M in each dNTP), 1  $\mu$ l of each oligonucleotide primer at 20  $\mu$ M (final concentration 0.8  $\mu$ M in each primer), and 1.25  $\mu$ l of cDNA. This was heated to 95°C for 5 min prior to the addition of MgCl<sub>2</sub> (2.5 mM final concentration) and 1 unit of *Taq* polymerase. Primers were synthesized by the Wistar Institute oligonucleotide synthesis facility. The samples were covered with a drop of mineral oil, and amplified with a Programmable Thermal Cycler (MJ Research, Watertown, MA). This program was: melting at 94°C for 3 min; 15 cycles of melting at 94°C for 1 min, annealing at 60°C for 1 min, elongation at 72°C for 1 min; 15 cycles of melting at 94°C for 1 min, annealing at 60°C for 1.5 min, elongation at 72°C for 2 min; final elongation at 72°C for 7 min; cooling to 4°C. The reaction products were run on a 3% agarose gel, stained with ethidium bromide, and photographed under UV light.

## RESULTS

### Primers

The primers utilized for a low-abundance message were derived from the sequence of the human *c-myc* oncogene.<sup>(3)</sup> The sequences are:

*c-myc* 5' 1763 GCTTCTCAGAGGCTTGG 1779  
*c-myc* 3' 2205 CGTCTAAGCAGCTGCAAG 2188

The primers utilized for a highly expressed message were derived from the sequences of human and murine  $\gamma$ -actin.<sup>(7-9)</sup> These sequences were aligned for maximal homology utilizing the programs Wordsearch and Segments.<sup>(10)</sup>



- zymatic amplification of DNA in vitro: The polymerase chain reaction. *Cold Spring Harbor Symp. Quant. Biol.* **51**: 263–273.
2. Mullis, K. and L. Faloona. 1987. Specific synthesis of DNA in vitro via a polymerase catalyzed chain reaction. *Methods Enzymol.* **155**: 335–350.
  3. Wang, A., M. Doyle, and D. Mark. 1989. Quantitation of mRNA by the polymerase chain reaction. *Proc. Natl. Acad. Sci.* **86**: 9717–9721.
  4. Sambrook, J., E. Fritsch, and T. Maniatis. 1989. *Molecular cloning: A laboratory manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
  5. Choi, Y., B. Kotzin, L. Herron, J. Callahan, P. Marrack, and J. Kappler. 1989. Interaction of *Staphylococcus aureus* toxin “superantigens” with human T cells. *Proc. Natl. Acad. Sci.* **86**: 8941–8945.
  6. Ausubel, F., R. Brent, R. Kingston, D. Moore, J. Seidman, J. Smith, and K. Struhl. 1989. *Current protocols in molecular biology*. Greene-Wiley, New York.
  7. Gunning, P., P. Ponte, H. Okayama, J. Engle, H. Blau, and L. Kedes. 1983. Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: Skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed. *Mol. Cell. Biol.* **3**: 787–795.
  8. Erba, H.P., P. Gunning, and L. Kedes. 1986. Nucleotide sequence of the human gamma cytoskeletal actin mRNA: Anomalous evolution of vertebrate non-muscle actin genes. *Nucleic Acids Res.* **14**: 5275–5294.
  9. Tokunaga, K., K. Takeda, K. Kamiyama, H. Kageyama, K. Takenaga, and S. Sakiyama. 1988. Isolation of cDNA clones for mouse cytoskeletal gamma-actin and differential expression of cytoskeletal actin mRNAs in mouse cells. *Mol. Cell. Biol.* **8**: 3929–3933.
  10. Devereux, J., P. Haeblerli, and O. Smithies. 1984. A comprehensive set of sequence analysis programs for the VAX. *Nucleic Acids Res.* **12**: 387–395.

Received April 1, 1992; accepted April 20, 1992.